A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the Kempinski Hotel Bristol - Salon Charlottenburg-Cecilienhof, Kurfürstendamm 27, D-10719, Berlin, Germany.
It will be hosted by pharmacogenomics research and development innovators HairDX and PsoriasisDX, pioneers of genetic tests for predicting the risk of male and female hair loss and for the risk of developing Psoriatic arthritis (PsA).
Featuring Hans Wolff, MD, the symposium will include speakers addressing the following topics:
- Genetics and Genomics - Sharon Keene, Chief Medical Officer, HairDX, LLC.
- Clinical Application: Genetics of Androgenetic Alopecia - Antonella Tosti, M.D.
- Clinical Application: Genetics of Psoriasis and Psoriatic Arthritis - Errol Prens, M.D., Ph.D.
“For dermatologists, this is an important educational seminar in the genetics of psoriasis, psoriatic arthritis and androgenetic alopecia,” says Dirk Segers, President of HairDX Europe. “HairDX and PsoriasisDX are pleased to share this knowledge as global innovators in molecular dermatology.”
The PsoriasisDX Genetic Test helps identify those at high risk for developing Psoriatic arthritis (PsA) before they experience arthritic symptoms, providing the opportunity to lessen joint damage through early medical intervention.
HairDX’s easy to use genetic test provides an accurate and understandable genetic analysis of a man’s or woman’s likelihood of developing Androgenetic Alopecia, the most common type of hair loss.
The HairDX (RxR) Genetic Test for Finasteride Response helps doctors predetermine if patients will have a subtle, moderate, or great treatment response to Finasteride, allowing the physician to provide patients with the best treatment regimen to save their hair.